BromeCare Therapeutics is rapidly developing a plant-derived therapeutic which disrupts SARS-CoV-2 spike protein as well as altering the ACE-2 and TMPRSS2 receptors that SARS-CoV-2 uses to gain entry into human cells for use in the treatment and prevention of COVID-19.
Double Helix Optics is designing and manufacturing sensors and imaging modules for precision 3D imaging used in life and material sciences, industrial inspection and machine vision to enable imaging and tracking of objects from single molecules inside cells (10-15 nm) to hand/face recognition with detailed 3D information utilizing patented light engineering technology.
Inherent Biosciences is a molecular diagnostics company at the intersection of epigenetics and artificial intelligence tackling clinical problems where epigenetics appears to be involved, namely: infertility, autoimmune disease, autism, and now COVID-19 disease severity and treatment response.
Laporte Immunotherapeutics, Inc. is a pre-clinical stage biopharmaceutical company developing transformative immune-based therapies for upper respiratory and eye infections, using immune stimulatory nanoparticles to activate immune defenses in the nose and eye.
Based on Nobel Prize-winning dual comb laser technology from NIST and CU Boulder, LongPath is attacking the climate change problem of undetected methane emissions from active oil wells by providing the lowest cost highest precision continuous methane monitoring for oil field installations in the world.
LumenAstra is commercializing a wearable, non-invasive core body temperature sensor with impactful applications in tumor hyperthermia therapy and monitoring brain temperature for neonates and stroke/brain injury patients to prevent additional brain damage during the critical hours post-injury.
Majelco Medical, Inc. is a seed-stage company that is developing a proprietary, disposable device to measure surgical blood loss accurately and in real-time, enabling improved patient outcomes and decreased healthcare costs for approximately 10 million surgeries every year in the U.S. alone.
Microsurgical Innovations (MSI) develops medical devices for use in microsurgical applications. MSI's first product for commercialization, a Vascular Coupling System (VCS), is intended to replace the hand suturing technique currently used to connect arteries and veins in microvascular and macrovascular end-to-end vascular repair surgeries.
PurCell Bio is developing a line of chemically defined, complete serum replacements specifically designed for individual cell types. These supplements minimize variability of results and eliminate contamination potential associated with serum and animal derived protein use. They support cells as well or better than serum and are similar in price.